Although real world evidence (RWE) is a hot topic in pharma right now, many still question whether it is acceptable to be used in regulatory decision making.
Real world evidence, patient centricity and new digital experiences are among the top 15 trends set to change clinical research and treatment commercialisation in 2020, according to Syneos